{"id":599657,"date":"2026-09-14T02:52:36","date_gmt":"2026-09-14T02:52:36","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/599657\/"},"modified":"2026-09-14T02:52:36","modified_gmt":"2026-09-14T02:52:36","slug":"home-cardiac-wire","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/599657\/","title":{"rendered":"Home – Cardiac Wire"},"content":{"rendered":"

\"\" <\/p>\n

\n Cardiology Business
\n August 10, 2026\n <\/p>\n

iRhythm Expands MCT Footprint with VitalConnect Acquisition August 10, 2026<\/p>\n

\n iRhythm, best known for its Zio cardiac monitoring wearables, is moving to expand well beyond its 14-day-patch roots by acquiring wearable biosensor company VitalConnect for $287.5M. <\/p>\n

\"\" <\/p>\n

\n Cardiology Pharmaceuticals
\n August 6, 2026\n <\/p>\n

ZEUS Tells Us Inflammation Might Not Be the Answer August 6, 2026<\/p>\n

\n Cardiovascular inflammation has been the talk of the town in cardiology, and while Novo Nordisk was wise to pursue treating it, results from the ZEUS trial have led to a thunderous debate on whether or not it ever played a role in ASCVD. <\/p>\n

\"\" <\/p>\n

\n Cardiology
\n August 3, 2026\n <\/p>\n

How to Make Cardiologists Love Academia Again August 3, 2026<\/p>\n

\n Cardiology is one of the most data-driven medical specialties a physician can pursue. So why is the source of that data \u2013 cardiac academia \u2013 declining in both workforce and prestige? <\/p>\n

\"\" <\/p>\n

\n Cardiology Pharmaceuticals
\n July 31, 2026\n <\/p>\n

Another Look at Attruby Reveals Bolstered Benefits July 31, 2026<\/p>\n

\n As the ATTR-CM market gets more crowded, medications will have to prove their place, and a sub-analysis of the ATTRibute-CM trial shows BridgeBio\u2019s Attruby (acoramidis) has the efficacy to remain competitive. <\/p>\n

\"\" <\/p>\n

\n Structural Heart
\n July 30, 2026\n <\/p>\n

Knowing When to Intervene in Mitral Regurgitation July 30, 2026<\/p>\n

\n A common question in structural heart cardiology is \u201cwhen do we know to intervene?\u201d and recently released 25-year mitral regurgitation data might just have given us an answer. <\/p>\n

\"\" <\/p>\n

\n Cardiology
\n July 27, 2026\n <\/p>\n

The Career Perceptions of Heart Failure Cardiology July 27, 2026<\/p>\n

\n Picture this \u2013 you graduate medical school (not easy), you do a three-year internal medicine residency, then a three-year general cardiology fellowship, and another year of fellowship, but you\u2019re paid less than your peers in other subspecialties \u2013 congrats, you\u2019re an advanced heart failure cardiologist (AHFTC). <\/p>\n

\"\" <\/p>\n

\n Cardiology Business
\n July 23, 2026\n <\/p>\n

The Cost of Cardiology is Driven by Insurers July 23, 2026<\/p>\n

\n New price transparency data reveals how wildly insurance payments, reimbursements, and facility fees for cardiology swing across insurers and states, which underscores the complexity of U.S. healthcare costs. <\/p>\n

\"\" <\/p>\n

\n Heart Failure
\n July 22, 2026\n <\/p>\n

How Earlier Hemodynamic Insight May Help Guide Heart Failure Management July 22, 2026<\/p>\n

\n Heart failure continues to place a significant burden on patients and the healthcare system, with nearly 7 million Americans living with heart failure, with prevalence expected to reach nearly 9 million by 2030. Despite advances in guideline-directed medical therapy (GDMT), many patients still face high risks of hospitalization, mortality, and reduced quality of life. <\/p>\n

\"\" <\/p>\n

\n Cardiology Pharmaceuticals
\n July 20, 2026\n <\/p>\n

An Oral PCSK9i and What it Means for Merck July 20, 2026<\/p>\n

\n PCSK9 inhibitors are some of the most effective LDL-lowering drugs out there, but they\u2019ve all required injection, and some even refrigeration. That just changed, however, with the FDA\u2019s approval of Merck’s Lipfendra (enlicitide), the first ever oral PCSK9i. <\/p>\n

\"\" <\/p>\n

\n Cardiology Pharmaceuticals
\n July 17, 2026\n <\/p>\n

Can Kerendia Handle the (Blood) Pressure? More Findings from FINEARTS-HF. July 17, 2026<\/p>\n

\n One year after its FDA approval for HF treatment, a new FINEARTS-HF substudy shows Bayer\u2019s Kerendia (finerenone) isn\u2019t just impervious to BP differences, it could actually give a small leg up to patients with hypertension. <\/p>\n

\"\" <\/p>\n

\n Cardiac Imaging
\n July 16, 2026\n <\/p>\n

Zero CAC And The Cost of CCTA-QPA July 16, 2026<\/p>\n

\n The power of a zero CAC score is facing fresh scrutiny after new plaque analysis data presented at SCCT 2026 shows just how much noncalcified plaque confers its own cardiovascular risk, despite the software\u2019s financial barriers. <\/p>\n

\"polypill\" <\/p>\n

\n Heart Failure
\n July 9, 2026\n <\/p>\n

POLY-HF and the Possibility of HF Polypills July 9, 2026<\/p>\n

\n Guideline-directed heart failure therapy works, but the biggest hurdle is getting patients to actually take it and fresh results in Nature from the POLY-HF trial suggest a polypill approach could be the answer. <\/p>\n","protected":false},"excerpt":{"rendered":"Cardiology Business August 10, 2026 iRhythm Expands MCT Footprint with VitalConnect Acquisition August 10, 2026 iRhythm, best known…\n","protected":false},"author":2,"featured_media":599658,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[134,111,139,69],"class_list":["post-599657","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/599657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=599657"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/599657\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/599658"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=599657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=599657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=599657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}